BeOne Medicines (BEIGF) Operating Leases (2019 - 2026)

BeOne Medicines (BEIGF) has reported Operating Leases for 8 consecutive years, with $48.2 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Operating Leases fell 10.64% year-over-year to $48.2 million in Q2 2026; TTM through Jun 2026 was $48.2 million, a 10.64% decrease from a year earlier, with the FY2025 full-year figure at $52.9 million, down 14.41% from the prior year.
• Operating Leases was $48.2 million for Q2 2026 at BeOne Medicines, down from $49.7 million in the prior quarter.
• Over five years, Operating Leases peaked at $61.9 million in Q4 2024 and troughed at $17.7 million in Q1 2024.
• A 5-year average of $42.4 million and a median of $43.1 million in 2022 frame the typical range for Operating Leases.
• Across the five-year window, Operating Leases tumbled 45.54% in 2024 and soared 209.76% in 2025, its largest moves.
• Over 5 years, Operating Leases stood at $58.6 million in 2022, then fell by 24.52% to $44.2 million in 2023, then surged by 39.94% to $61.9 million in 2024, then retreated by 14.41% to $52.9 million in 2025, then retreated by 8.95% to $48.2 million in 2026.
• The last three Operating Leases figures came in at $48.2 million (Q2 2026), $49.7 million (Q1 2026), and $52.9 million (Q4 2025), per Business Quant data.